Restricted Access

Before you enter

All products are sold strictly for in-vitro laboratory research — not for human consumption, therapeutic, or veterinary use.

Your confirmation is saved for 7 days. You will only be asked to confirm once per week.
By entering you accept full responsibility for compliance with all applicable laws.

For research use only  ·  Not for human or animal consumption
Home/Products/CJC-1295 / Ipamorelin
CJC-1295 / Ipamorelin research vial Third-party tested
Secretagogue Peptide

CJC-1295 / Ipamorelin

Modified GRF + Ipamorelin
Mod GRF 1-29 + IpamorelinCJC/Ipa Blend

A research blend of Modified GRF(1-29) and Ipamorelin, studied at the GHRH and ghrelin (GHSR-1a) receptors.

$55.00$5.50 / mg
Strength

Availability: 10 in stock

Fast U.S. shippingFree on orders over $200
Third-party testedIndependent lab, every batch
Purity documentedHPLC + mass spec
Secure checkoutVenmo · Cash App · Zelle
01Research snapshot

CJC-1295 / Ipamorelin, by the numbers.

Structural and laboratory facts that define this compound. For laboratory research use only.

0
Compounds

Mod GRF(1-29) + Ipamorelin

0
Mod GRF residues

GHRH(1-29) with 4 substitutions

0
Ipamorelin residues

Selective GHSR-1a pentapeptide

0:1
Blend ratio

5 mg + 5 mg per vial

02Mechanism of action

How it is studied.

Two complementary pituitary receptor pathways activated simultaneously for synergistic GH pulse enhancement

01
GHRH-R Pathway CJC-1295: GHRH Receptor Activation

CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, stimulating cAMP production and GH synthesis. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, enabling a sustained window of GHRH-R activation per dose.

  • GHRH-R agonism — cAMP-mediated GH synthesis
  • ~30-minute half-life for time-matched dosing
  • Cortisol, thyroid, prolactin unaffected
02
GHSR-1a Pathway Ipamorelin: Ghrelin Receptor Activation

Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.

  • GHSR-1a agonism — PLC/IP3 intracellular pathway
  • No cortisol, ACTH, or prolactin co-secretion
  • ~2-hour half-life — pulsatile GH release
03
Synergy Dual-Pathway Synergistic GH Amplification

When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude exceeds what either compound produces alone. Preclinical data show this additive-to-synergistic interaction: each pathway potentiates the other's pituitary response, producing larger GH pulses without proportionally increasing side effects.

  • Additive GH pulse amplitude vs either alone
  • Somatostatin suppression potentiated by GHSR agonism
  • Physiologic pulsatile pattern preserved

Research pathway map

The primary pathways CJC-1295 / Ipamorelin is investigated against in laboratory models.

CJC-1295 / IpamorelinTARGETS01GHRH-R Pathway02GHSR-1a Pathway03Synergy
Illustrative schematic based on published in-vitro and preclinical observations. Research use only.
03Specifications

Compound details.

Chemical nameModified GRF(1-29) + Ipamorelin
SynonymsModified GRF + Ipamorelin, Mod GRF 1-29 + Ipamorelin, CJC/Ipa Blend
FormLyophilized powder
DocumentationThird-party COA, per batch

Storage & handling

Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.

FOR RESEARCH USE ONLYNot for human or animal consumption. Intended strictly for qualified researchers performing in-vitro or analytical laboratory work. No medical, diagnostic or therapeutic claims are made.
Eur J Endocrinol · 1998Ipamorelin, the first selective growth hormone secretagogue

Ipamorelin component: original characterization.

Raun K et al., 1998 · PubMed ↗
Endocrinology · 2005hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats

GRF(1-29) analog research at the pituitary GRF receptor.

Jetté L et al., 2005 · PubMed ↗
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Scroll to Top